Clinical Trial Update: A Study to Evaluate the Combination of Pegylated Interferon Alfa Plus Valopicitabine in Patients With Hepatitis C [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of pegylated interferon alfa and valopicitabine for chronic hepatitis C has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon alfa (pegylated interferon alfa)
• Valopicitabine (valopicitabine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C | Phase 2 | Status: COMPLETED